Print

Positive preclinical results for Active Biotech's project 57-57 for the treatment of SLE

2003-10-27

Oral treatment with doses of 2 or 12 mg/kg of ABR-215757 per day resulted in a statistically significant decrease of kidney inflammation, measured as protein level and blood in the urine, compared to the control group. As a consequence, the survival of the animals treated with ABR-215757 was increased. A similar result was seen regardless of whether the animals were treated at an early or late stage of the disease process. These results indicate that ABR-215757 could offer a new treatment alternative for SLE patients.
Lund, October 27, 2003
Active Biotech AB (publ)
Sven Andréasson
President & CEO
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50

pdf



Back